Thalassemia. Beta thalassaemia
Conditions
Interventions
Intervention 1: Intervention group 2: patients treated with DFP alone (75 mg/kg, daily). Intervention 2: Control group: patients treated with DFO alone (50 mg/kg, 5 days weekly). Intervention 3: Inter
Treatment - Drugs
Intervention group 2: patients treated with DFP alone (75 mg/kg, daily)
Control group: patients treated with DFO alone (50 mg/kg, 5 days weekly)
Intervention group 1: patients treated with DFP given at a daily dose of 75 mg/kg in combination with DFO (50 mg/kg, twice weekly)
Sponsors
Vice Chancellor for research of Urmia University of Medical Sciences
Eligibility
Sex/Gender
All
Age
3 Years to 18 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Transfusion-dependent Thalassemia; Age more than three years; Serum ferritin level > 5,000 ng/L and progressively increasing undergoing chelating therapy with subcutaneous DFO Exclusion Criteria: Severe liver, kidney or cardiac disease; Serious adverse events with DFO or DFP; Neutriphil count < 2000/L during the past 2 years; Platelet count < 100,000/L; History of arthropathy
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum ferritin. Timepoint: before intervention and in 2, 4, 6, 8, 10 and 12 month intervals after intervention. Method of measurement: ng/mL. | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete blood count. Timepoint: before intervention and monthly for 12 month after intervention. Method of measurement: blood examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMostafa Qorbani
Alborz University of Medical Sciences
Outcome results
None listed